

ASSIGNMENT

THIS ASSIGNMENT is made BETWEEN

Martin Quibell, c/o Acadia Pharmaceuticals Inc., 12830 El Camino Real, Suite 400, San Diego, CA 92130; (hereinafter called "the Assignor");

AND

MAQU Limited, Bank Gallery, 13 High Street Kenilworth, Warwickshire, CV8 1LY (hereinafter called "the Assignee").

WHEREAS

(A) The Assignor is an inventor of inventions relating to MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 (hereinafter referred to as "the Inventions"), which are the subject of the patent applications listed on the SCHEDULE attached hereto (hereinafter "the Applications");

(B) The Assignor and the Assignee have agreed that all the Assignor's rights in the Invention and the Applications should be transferred by the Assignor to the Assignee for the consideration hereinafter set forth.

NOW THEREFORE, in consideration of the sum of £1 paid by the Assignee to the Assignor (the receipt of which is hereby acknowledged):

1. Assignment. Assignor hereby irrevocably conveys, transfers, and assigns to Assignee, and Assignee hereby accepts, all of Assignor's right, title, and interest in and to the following:

(a) all rights, privileges, and protections of any kind whatsoever of Assignor accruing under the Invention and any intellectual property rights therein, provided under the applicable law of any jurisdiction, bylaw, international treaties, conventions or otherwise throughout the world;

(b) the Applications, all patents that issue from the Applications, and all continuations, continuations-in-part, divisionals, extensions, substitutions, reissues, re-examinations and renewals, of any of the foregoing, and any patents or patent applications from which any of them claim priority or that claim priority from any of them, and all inventions disclosed and claimed in any of the foregoing, and the right to claim priority to any of the foregoing;

(c) all rights, privileges, and protections of any kind whatsoever of Assignor accruing under any of the Applications provided under the applicable law of any jurisdiction, by international treaties and conventions and otherwise throughout the world, including, but not limited to, the right to file foreign patent applications and license recordations; and

(d) any and all claims and causes of action, with respect to the Inventions or the Applications, whether accruing before, on or after the effective date of this Agreement, including all rights to and claims for damages, restitution and injunctive and other legal and equitable relief for past, present and future infringement, misappropriation, violation, misuse, breach or default, with the right but no obligation to petition or sue for, or otherwise seek, such legal and equitable relief and to collect, or otherwise recover, any such damages.

2. Recordation. The Assignor authorizes the Commissioner for Patents and any other governmental officials to record and register this Agreement.

3. Further Actions. The Assignor agrees:

(a) to execute (i) all necessary papers throughout the world to be used in connection with the Applications as Assignee may deem necessary or expedient, (ii) all papers in connection with any interference, legal or other proceedings throughout the world to maintain, protect or enforce, or otherwise relating to, the Applications, and (iii) all papers and documents which may be necessary throughout the world in connection with the preparation and filing of any applications for the Invention and the Applications;

(b) to cooperate with Assignee at Assignee's expense in every way reasonably possible in obtaining evidence related to the Invention and the Applications going forward in any proceedings related to the Applications throughout the world; and

(c) at Assignee's expense to perform all other affirmative acts which in Assignee's reasonable discretion may be necessary or desirable throughout the world to maintain, protect or enforce the Applications or patents granting therefrom.

4. Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

5. Representations and Warranties. The Assignor represents and warrants to the Assignor that: the Assignor has the full right to convey the interest assigned by this Assignment; and that the Assignor has not granted any license to the Invention or the Applications.

6. Successors and Assigns. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns.

7. Choice of Law. This Agreement and any non-contractual obligations arising out of or in connection with it will be governed by and construed in accordance with the laws of England, without taking account of any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The courts of England will have non-exclusive jurisdiction to settle any disputes which may arise out of or in connection with this Agreement. The parties irrevocably agree to submit to that jurisdiction, save that nothing will prevent either party from seeking injunctive relief or enforcing a judgment of the English courts in any appropriate jurisdiction.

IN WITNESS WHEREOF THE PARTIES HERETO HAVE EXECUTED THIS ASSIGNMENT

EXECUTED BY ASSIGNOR

MQuibell.

Date: Jul 22, 2024

Name: Martin Quibell

Witnessed by:

Adele Quibell

Date: Jul 22, 2024

Name: Adele Quibell

EXECUTED ON BEHALF OF THE ASSIGNEE BY

MQuibell.

Date: Jul 22, 2024

Name: Martin Quibell

Title: Shareholder MAQU Limited

Witnessed by:

Adele Quibell

Date: Jul 22, 2024

Name: Adele Quibell

SCHEDULE

Application No.	Filing Date	Title
PCT/US2023/025936	22 June 2023	MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88
PCT/US2023/025937	22 June 2023	MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88

ASSIGNMENT

THIS ASSIGNMENT is made

BETWEEN

- (1) **Woodyett Consulting Limited**, 2 Old Bath Road Newbury Berkshire RG14 1QL ("**Assignor**")
- (2) **PANDEIA THERAPEUTICS LIMITED** (registered number 11463856) whose registered office is at C/O The Cambridge Partnership Limited, The Dorothy Hodgkin Building, Babraham Research Campus, Babraham, Cambridge, UK CB22 3FH ("**Assignee**")

BACKGROUND

- (A) The parties are entering into this Assignment to confirm the vesting of the Invention(s) and the Applications in the Assignee on the terms set out in this Assignment.

OPERATIVE PROVISIONS

1. In this Assignment, the following expressions have the following meanings unless inconsistent with the context:

Applications means the applications listed in the **Schedule** to this Assignment.

Invention(s) means the invention(s) specified in the Applications.

Patents means granted patents or similar registered rights which derive from any of the Applications and any other application for a patent or similar registered right for the Invention(s) or any applications for continuations, divisionals, reissues, re-examinations, extensions, substitutions and continuations in part in respect of any such application.

2. In consideration of good and valuable consideration of ten pounds sterling, the receipt and sufficiency of which is acknowledged by the Assignor, the Assignor assigns to the Assignee (to the extent that they have not already vested in the Assignee at law or under contract) all its worldwide right, title and interest in the Invention(s) and the Applications absolutely and the full and exclusive benefit of the Invention(s) and the Applications including, without limitation:
 - 2.1 all rights to apply for patents or similar registered rights for the Invention(s) and to prosecute the Applications and such other applications to obtain Patents throughout the world, including the right to priority, and any priorities claimed by such applications so that the grant of any Patent shall be in the name of and vest in the Assignee or its successor(s) in title or assignee(s); and
 - 2.2 all rights to any and all future applications for continuations, divisionals, reissues, re-examinations, extensions, substitutions and continuations in part in respect of the Invention(s) and the Applications (and any part of them) as well as the worldwide right to be granted and hold Patents; and
 - 2.3 all rights and powers arising or accrued from the Invention(s) and the Applications and any

Patents before, on, or after the date of this Assignment, including any right:

2.3.1 to bring, make, oppose, defend, appeal proceedings, claims or actions; and

2.3.2 to obtain relief (damages and other remedies) in respect of infringement or alleged infringement of, or any other cause of action

arising from ownership of, all or any of rights in the Invention(s) and the Applications, including (without limitation) any right to have the benefit of any relief obtained on such infringement before the date of this Assignment.

3. The Assignee accepts the assignment of the Invention(s) and the Applications and all other rights assigned by this Assignment.
4. The Assignor agrees that it will promptly:
 - 4.1 execute all documents, take all such actions and proceedings, do all things and provide all reasonable assistance to secure the right, title and interest in the Invention(s) assigned to the Assignee by this Assignment, including:
 - 4.1.1 registration of the Assignee as applicant for the Applications and any other application for a patent or similar registered rights for the Invention(s), or as proprietor of the Patents; and
 - 4.1.2 assisting the Assignee in obtaining, defending and enforcing the Patents, and assisting with any other proceedings which may be brought by or against the Assignee against or by any third party relating to the rights assigned by this Assignment; and
5. The rights transferred by this Assignment and the benefits of this Assignment will be enforceable by the Assignee together with any successor(s) in title or assignee(s).
6. The failure to exercise or delay in exercising a right or remedy under this Assignment shall not constitute a waiver of the right or remedy or a waiver of any other rights or remedies, and no single or partial exercise of any right or remedy under this Assignment shall prevent any further exercise of the right or remedy or the exercise of any other right or remedy.
7. All headings in this Assignment are for ease of reference only and will not affect the construction or interpretation of this Assignment.
8. This Assignment and any non-contractual obligations arising out of or in connection with it shall be governed by and construed in accordance with the laws of England.
9. The courts of England and Wales will have non-exclusive jurisdiction to settle disputes which may arise out of or in connection with this Assignment. The parties irrevocably agree to submit to that jurisdiction, save that nothing shall prevent either party from seeking injunctive relief in any appropriate jurisdiction.

ON AGREEMENT
Signatures on page 3

IN WITNESS WHEREOF THE PARTIES HERETO HAVE EXECUTED THIS ASSIGNMENT

EXECUTED BY ASSIGNOR



Date: Jul 23, 2024

Name: Fraser Murray

Title: Shareholder Woodyett Consulting Limited

Witnessed by:



Date: Jul 23, 2024

Name: Veronica Porkess

EXECUTED ON BEHALF OF THE ASSIGNEE BY



Date: Jul 26, 2024

Name: Jennifer Rhodes

Title: Director, Pandeia Therapeutics Limited

Witnessed by:



Date: Jul 26, 2024

Name: Diane DeWitt

Schedule

Application No.	Filing Date	Title
PCT/US2023/025936	22 June 2023	MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88
PCT/US2023/025937	22 June 2023	MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88

ASSIGNMENT

THIS ASSIGNMENT is made BETWEEN

Timothy Schulz-Utermoehl, c/o Acadia Pharmaceuticals Inc., 12830 El Camino Real, Suite 400, San Diego, CA 92130; (hereinafter called "the Assignor");

AND

DMPK Consulting Limited, 10 Brookfield Road Lymm, Cheshire, United Kingdom WA13 0QJ (hereinafter called "the Assignee").

WHEREAS

(A) The Assignor is an inventor of inventions relating to MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 (hereinafter referred to as "the Inventions"), which are the subject of the patent applications listed on the SCHEDULE attached hereto (hereinafter "the Applications");

(B) The Assignor and the Assignee have agreed that all the Assignor's rights in the Invention and the Applications should be transferred by the Assignor to the Assignee for the consideration hereinafter set forth.

NOW THEREFORE, in consideration of the sum of £1 paid by the Assignee to the Assignor (the receipt of which is hereby acknowledged):

1. Assignment. Assignor hereby irrevocably conveys, transfers, and assigns to Assignee, and Assignee hereby accepts, all of Assignor's right, title, and interest in and to the following:

(a) all rights, privileges, and protections of any kind whatsoever of Assignor accruing under the Invention and any intellectual property rights therein, provided under the applicable law of any jurisdiction, bylaw, international treaties, conventions or otherwise throughout the world;

(b) the Applications, all patents that issue from the Applications, and all continuations, continuations-in-part, divisionals, extensions, substitutions, reissues, re-examinations and renewals, of any of the foregoing, and any patents or patent applications from which any of them claim priority or that claim priority from any of them, and all inventions disclosed and claimed in any of the foregoing, and the right to claim priority to any of the foregoing;

(c) all rights, privileges, and protections of any kind whatsoever of Assignor accruing under any of the Applications provided under the applicable law of any jurisdiction, by international treaties and conventions and otherwise throughout the world, including, but not limited to, the right to file foreign patent applications and license recordations; and

(d) any and all claims and causes of action, with respect to the Inventions or the Applications, whether accruing before, on or after the effective date of this Agreement, including all rights to and claims for damages, restitution and injunctive and other legal and equitable relief for past, present and future infringement, misappropriation, violation, misuse, breach or default, with the right but no obligation to petition or sue for, or otherwise seek, such legal and equitable relief and to collect, or otherwise recover, any such damages.

2. Recordation. The Assignor authorizes the Commissioner for Patents and any other governmental officials to record and register this Agreement.

3. Further Actions. The Assignor agrees:

(a) to execute (i) all necessary papers throughout the world to be used in connection with the Applications as Assignee may deem necessary or expedient, (ii) all papers in connection with any interference, legal or other proceedings throughout the world to maintain, protect or enforce, or otherwise relating to, the Applications, and (iii) all papers and documents which may be necessary throughout the world in connection with the preparation and filing of any applications for the Invention and the Applications;

(b) to cooperate with Assignee at Assignee's expense in every way reasonably possible in obtaining evidence related to the Invention and the Applications going forward in any proceedings related to the Applications throughout the world; and

(c) at Assignee's expense to perform all other affirmative acts which in Assignee's reasonable discretion may be necessary or desirable throughout the world to maintain, protect or enforce the Applications or patents granting therefrom.

4. Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

5. Representations and Warranties. The Assignor represents and warrants to the Assignor that: the Assignor has the full right to convey the interest assigned by this Assignment; and that the Assignor has not granted any license to the Invention or the Applications.

6. Successors and Assigns. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns.

7. Choice of Law. This Agreement and any non-contractual obligations arising out of or in connection with it will be governed by and construed in accordance with the laws of England, without taking account of any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The courts of England will have non-exclusive jurisdiction to settle any disputes which may arise out of or in connection with this Agreement. The parties irrevocably agree to submit to that jurisdiction, save that nothing will prevent either party from seeking injunctive relief or enforcing a judgment of the English courts in any appropriate jurisdiction.


IN WITNESS WHEREOF THE PARTIES HERETO HAVE EXECUTED THIS ASSIGNMENT

EXECUTED BY ASSIGNOR



Date: Jul 22, 2024

Name: Timothy Schulz-Utermoehl

Witnessed by:


Date: Jul 23, 2024

Name: Vanessa Theis


EXECUTED ON BEHALF OF THE ASSIGNEE BY



Date: Jul 22, 2024

Name: Timothy Schulz-Utermoehl

Title: Shareholder DMPK Consulting Limited

Witnessed by:


Date: Jul 23, 2024

Name: Vanessa Theis

SCHEDULE

Application No.	Filing Date	Title
PCT/US2023/025936	22 June 2023	MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88
PCT/US2023/025937	22 June 2023	MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88

ASSIGNMENT

THIS ASSIGNMENT is made

BETWEEN

- (1) **MAQU Limited**, Bank Gallery, 13 High Street Kenilworth, Warwickshire, CV8 1LY ("**Assignor**")
- (2) **PANDEIA THERAPEUTICS LIMITED** (registered number 11463856) whose registered office is at C/O The Cambridge Partnership Limited, The Dorothy Hodgkin Building, Babraham Research Campus, Babraham, Cambridge, UK CB22 3FH ("**Assignee**")

BACKGROUND

- (A) The parties are entering into this Assignment to confirm the vesting of the Invention(s) and the Applications in the Assignee on the terms set out in this Assignment.

OPERATIVE PROVISIONS

1. In this Assignment, the following expressions have the following meanings unless inconsistent with the context:

Applications means the applications listed in the **Schedule** to this Assignment.

Invention(s) means the invention(s) specified in the Applications.

Patents means granted patents or similar registered rights which derive from any of the Applications and any other application for a patent or similar registered right for the Invention(s) or any applications for continuations, divisionals, reissues, re-examinations, extensions, substitutions and continuations in part in respect of any such application.

2. In consideration of good and valuable consideration of ten pounds sterling, the receipt and sufficiency of which is acknowledged by the Assignor, the Assignor assigns to the Assignee (to the extent that they have not already vested in the Assignee at law or under contract) all its worldwide right, title and interest in the Invention(s) and the Applications absolutely and the full and exclusive benefit of the Invention(s) and the Applications including, without limitation:
 - 2.1 all rights to apply for patents or similar registered rights for the Invention(s) and to prosecute the Applications and such other applications to obtain Patents throughout the world, including the right to priority, and any priorities claimed by such applications so that the grant of any Patent shall be in the name of and vest in the Assignee or its successor(s) in title or assignee(s); and
 - 2.2 all rights to any and all future applications for continuations, divisionals, reissues, re-examinations, extensions, substitutions and continuations in part in respect of the Invention(s) and the Applications (and any part of them) as well as the worldwide right to be granted and hold Patents; and
 - 2.3 all rights and powers arising or accrued from the Invention(s) and the Applications and any

Patents before, on, or after the date of this Assignment, including any right:

2.3.1 to bring, make, oppose, defend, appeal proceedings, claims or actions; and

2.3.2 to obtain relief (damages and other remedies) in respect of infringement or alleged infringement of, or any other cause of action

arising from ownership of, all or any of rights in the Invention(s) and the Applications, including (without limitation) any right to have the benefit of any relief obtained on such infringement before the date of this Assignment.

3. The Assignee accepts the assignment of the Invention(s) and the Applications and all other rights assigned by this Assignment.
4. The Assignor agrees that it will promptly:
 - 4.1 execute all documents, take all such actions and proceedings, do all things and provide all reasonable assistance to secure the right, title and interest in the Invention(s) assigned to the Assignee by this Assignment, including:
 - 4.1.1 registration of the Assignee as applicant for the Applications and any other application for a patent or similar registered rights for the Invention(s), or as proprietor of the Patents; and
 - 4.1.2 assisting the Assignee in obtaining, defending and enforcing the Patents, and assisting with any other proceedings which may be brought by or against the Assignee against or by any third party relating to the rights assigned by this Assignment; and
5. The rights transferred by this Assignment and the benefits of this Assignment will be enforceable by the Assignee together with any successor(s) in title or assignee(s).
6. The failure to exercise or delay in exercising a right or remedy under this Assignment shall not constitute a waiver of the right or remedy or a waiver of any other rights or remedies, and no single or partial exercise of any right or remedy under this Assignment shall prevent any further exercise of the right or remedy or the exercise of any other right or remedy.
7. All headings in this Assignment are for ease of reference only and will not affect the construction or interpretation of this Assignment.
8. This Assignment and any non-contractual obligations arising out of or in connection with it shall be governed by and construed in accordance with the laws of England.
9. The courts of England and Wales will have non-exclusive jurisdiction to settle disputes which may arise out of or in connection with this Assignment. The parties irrevocably agree to submit to that jurisdiction, save that nothing shall prevent either party from seeking injunctive relief in any appropriate jurisdiction.

ON AGREEMENT
Signatures on page 3

IN WITNESS WHEREOF THE PARTIES HERETO HAVE EXECUTED THIS ASSIGNMENT

EXECUTED BY ASSIGNOR

M Quibell.

Date: Jul 22, 2024

Name: Martin Quibell

Title: Shareholder MAQU Limited

Witnessed by:

Adele Quibell

Date: Jul 22, 2024

Name: Adele Quibell

EXECUTED ON BEHALF OF THE ASSIGNEE BY

Jr

Date: Jul 26, 2024

Name: Jennifer Rhodes

Title: Director, Pandeia Therapeutics Limited

Witnessed by:

Diane E. DeWitt

Date: Jul 26, 2024

Name: Diane DeWitt

Schedule

Application No.	Filing Date	Title
PCT/US2023/025936	22 June 2023	MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88
PCT/US2023/025937	22 June 2023	MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88

ASSIGNMENT

THIS ASSIGNMENT is made

BETWEEN

- (1) **DMPK Consulting Limited**, 10 Brookfield Road Lymm, Cheshire, United Kingdom WA13 0QJ (“**Assignor**”)
- (2) **PANDEIA THERAPEUTICS LIMITED** (registered number 11463856) whose registered office is at C/O The Cambridge Partnership Limited, The Dorothy Hodgkin Building, Babraham Research Campus, Babraham, Cambridge, UK CB22 3FH (“**Assignee**”)

BACKGROUND

- (A) The parties are entering into this Assignment to confirm the vesting of the Invention(s) and the Applications in the Assignee on the terms set out in this Assignment.

OPERATIVE PROVISIONS

1. In this Assignment, the following expressions have the following meanings unless inconsistent with the context:

Applications means the applications listed in the **Schedule** to this Assignment.

Invention(s) means the invention(s) specified in the Applications.

Patents means granted patents or similar registered rights which derive from any of the Applications and any other application for a patent or similar registered right for the Invention(s) or any applications for continuations, divisionals, reissues, re-examinations, extensions, substitutions and continuations in part in respect of any such application.

2. In consideration of good and valuable consideration of ten pounds sterling, the receipt and sufficiency of which is acknowledged by the Assignor, the Assignor assigns to the Assignee (to the extent that they have not already vested in the Assignee at law or under contract) all its worldwide right, title and interest in the Invention(s) and the Applications absolutely and the full and exclusive benefit of the Invention(s) and the Applications including, without limitation:
- 2.1 all rights to apply for patents or similar registered rights for the Invention(s) and to prosecute the Applications and such other applications to obtain Patents throughout the world, including the right to priority, and any priorities claimed by such applications so that the grant of any Patent shall be in the name of and vest in the Assignee or its successor(s) in title or assignee(s); and
- 2.2 all rights to any and all future applications for continuations, divisionals, reissues, re-examinations, extensions, substitutions and continuations in part in respect of the Invention(s) and the Applications (and any part of them) as well as the worldwide right to be granted and hold Patents; and
- 2.3 all rights and powers arising or accrued from the Invention(s) and the Applications and any

Patents before, on, or after the date of this Assignment, including any right:

2.3.1 to bring, make, oppose, defend, appeal proceedings, claims or actions; and

2.3.2 to obtain relief (damages and other remedies) in respect of infringement or alleged infringement of, or any other cause of action

arising from ownership of, all or any of rights in the Invention(s) and the Applications, including (without limitation) any right to have the benefit of any relief obtained on such infringement before the date of this Assignment.

3. The Assignee accepts the assignment of the Invention(s) and the Applications and all other rights assigned by this Assignment.
4. The Assignor agrees that it will promptly:
 - 4.1 execute all documents, take all such actions and proceedings, do all things and provide all reasonable assistance to secure the right, title and interest in the Invention(s) assigned to the Assignee by this Assignment, including:
 - 4.1.1 registration of the Assignee as applicant for the Applications and any other application for a patent or similar registered rights for the Invention(s), or as proprietor of the Patents; and
 - 4.1.2 assisting the Assignee in obtaining, defending and enforcing the Patents, and assisting with any other proceedings which may be brought by or against the Assignee against or by any third party relating to the rights assigned by this Assignment; and
5. The rights transferred by this Assignment and the benefits of this Assignment will be enforceable by the Assignee together with any successor(s) in title or assignee(s).
6. The failure to exercise or delay in exercising a right or remedy under this Assignment shall not constitute a waiver of the right or remedy or a waiver of any other rights or remedies, and no single or partial exercise of any right or remedy under this Assignment shall prevent any further exercise of the right or remedy or the exercise of any other right or remedy.
7. All headings in this Assignment are for ease of reference only and will not affect the construction or interpretation of this Assignment.
8. This Assignment and any non-contractual obligations arising out of or in connection with it shall be governed by and construed in accordance with the laws of England.
9. The courts of England and Wales will have non-exclusive jurisdiction to settle disputes which may arise out of or in connection with this Assignment. The parties irrevocably agree to submit to that jurisdiction, save that nothing shall prevent either party from seeking injunctive relief in any appropriate jurisdiction.

ON AGREEMENT
Signatures on page 3

IN WITNESS WHEREOF THE PARTIES HERETO HAVE EXECUTED THIS ASSIGNMENT

EXECUTED BY ASSIGNOR




Date: Jul 22, 2024

Name: Timothy Schulz-Utermoehl

Title: Shareholder DMPK Consulting Limited

Witnessed by:



Date: Jul 23, 2024

Name: Vanessa Theis

EXECUTED ON BEHALF OF THE ASSIGNEE BY




Date: Jul 23, 2024

Name: Jennifer Rhodes

Title: Director, Pandeia Therapeutics Limited

Witnessed by:



Date: Jul 23, 2024

Name: Diane DeWitt

Schedule

Application No.	Filing Date	Title
PCT/US2023/025936	22 June 2023	MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88
PCT/US2023/025937	22 June 2023	MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88

ASSIGNMENT

THIS ASSIGNMENT is made

BETWEEN

- (1) **MAQU Limited**, Bank Gallery, 13 High Street Kenilworth, Warwickshire, CV8 1LY ("**Assignor**")
- (2) **PANDEIA THERAPEUTICS LIMITED** (registered number 11463856) whose registered office is at C/O The Cambridge Partnership Limited, The Dorothy Hodgkin Building, Babraham Research Campus, Babraham, Cambridge, UK CB22 3FH ("**Assignee**")

BACKGROUND

- (A) The parties are entering into this Assignment to confirm the vesting of the Invention(s) and the Applications in the Assignee on the terms set out in this Assignment.

OPERATIVE PROVISIONS

1. In this Assignment, the following expressions have the following meanings unless inconsistent with the context:

Applications means the applications listed in the **Schedule** to this Assignment.

Invention(s) means the invention(s) specified in the Applications.

Patents means granted patents or similar registered rights which derive from any of the Applications and any other application for a patent or similar registered right for the Invention(s) or any applications for continuations, divisionals, reissues, re-examinations, extensions, substitutions and continuations in part in respect of any such application.

2. In consideration of good and valuable consideration of ten pounds sterling, the receipt and sufficiency of which is acknowledged by the Assignor, the Assignor assigns to the Assignee (to the extent that they have not already vested in the Assignee at law or under contract) all its worldwide right, title and interest in the Invention(s) and the Applications absolutely and the full and exclusive benefit of the Invention(s) and the Applications including, without limitation:
 - 2.1 all rights to apply for patents or similar registered rights for the Invention(s) and to prosecute the Applications and such other applications to obtain Patents throughout the world, including the right to priority, and any priorities claimed by such applications so that the grant of any Patent shall be in the name of and vest in the Assignee or its successor(s) in title or assignee(s); and
 - 2.2 all rights to any and all future applications for continuations, divisionals, reissues, re-examinations, extensions, substitutions and continuations in part in respect of the Invention(s) and the Applications (and any part of them) as well as the worldwide right to be granted and hold Patents; and
 - 2.3 all rights and powers arising or accrued from the Invention(s) and the Applications and any

Patents before, on, or after the date of this Assignment, including any right:

2.3.1 to bring, make, oppose, defend, appeal proceedings, claims or actions; and

2.3.2 to obtain relief (damages and other remedies) in respect of infringement or alleged infringement of, or any other cause of action

arising from ownership of, all or any of rights in the Invention(s) and the Applications, including (without limitation) any right to have the benefit of any relief obtained on such infringement before the date of this Assignment.

3. The Assignee accepts the assignment of the Invention(s) and the Applications and all other rights assigned by this Assignment.
4. The Assignor agrees that it will promptly:
 - 4.1 execute all documents, take all such actions and proceedings, do all things and provide all reasonable assistance to secure the right, title and interest in the Invention(s) assigned to the Assignee by this Assignment, including:
 - 4.1.1 registration of the Assignee as applicant for the Applications and any other application for a patent or similar registered rights for the Invention(s), or as proprietor of the Patents; and
 - 4.1.2 assisting the Assignee in obtaining, defending and enforcing the Patents, and assisting with any other proceedings which may be brought by or against the Assignee against or by any third party relating to the rights assigned by this Assignment; and
5. The rights transferred by this Assignment and the benefits of this Assignment will be enforceable by the Assignee together with any successor(s) in title or assignee(s).
6. The failure to exercise or delay in exercising a right or remedy under this Assignment shall not constitute a waiver of the right or remedy or a waiver of any other rights or remedies, and no single or partial exercise of any right or remedy under this Assignment shall prevent any further exercise of the right or remedy or the exercise of any other right or remedy.
7. All headings in this Assignment are for ease of reference only and will not affect the construction or interpretation of this Assignment.
8. This Assignment and any non-contractual obligations arising out of or in connection with it shall be governed by and construed in accordance with the laws of England.
9. The courts of England and Wales will have non-exclusive jurisdiction to settle disputes which may arise out of or in connection with this Assignment. The parties irrevocably agree to submit to that jurisdiction, save that nothing shall prevent either party from seeking injunctive relief in any appropriate jurisdiction.

ON AGREEMENT
Signatures on page 3

IN WITNESS WHEREOF THE PARTIES HERETO HAVE EXECUTED THIS ASSIGNMENT

EXECUTED BY ASSIGNOR

M Quibell.

Date: Jul 22, 2024

Name: Martin Quibell

Title: Shareholder MAQU Limited

Witnessed by:

Adele Quibell

Date: Jul 22, 2024

Name: Adele Quibell

EXECUTED ON BEHALF OF THE ASSIGNEE BY

Jr

Date: Jul 26, 2024

Name: Jennifer Rhodes

Title: Director, Pandeia Therapeutics Limited

Witnessed by:

Diane E. DeWitt

Date: Jul 26, 2024

Name: Diane DeWitt

Schedule

Application No.	Filing Date	Title
PCT/US2023/025936	22 June 2023	MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88
PCT/US2023/025937	22 June 2023	MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88

ASSIGNMENT

THIS ASSIGNMENT is made BETWEEN

Fraser Murray, c/o Acadia Pharmaceuticals Inc., 12830 El Camino Real, Suite 400, San Diego, CA 92130; (hereinafter called "the Assignor");

AND

Woodyett Consulting Limited, 2 Old Bath Road Newbury Berkshire RG14 1QL (hereinafter called "the Assignee").

WHEREAS

(A) The Assignor is an inventor of inventions relating to MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 (hereinafter referred to as "the Inventions"), which are the subject of the patent applications listed on the SCHEDULE attached hereto (hereinafter "the Applications");

(B) The Assignor and the Assignee have agreed that all the Assignor's rights in the Invention and the Applications should be transferred by the Assignor to the Assignee for the consideration hereinafter set forth.

NOW THEREFORE, in consideration of the sum of £1 paid by the Assignee to the Assignor (the receipt of which is hereby acknowledged):

1. Assignment. Assignor hereby irrevocably conveys, transfers, and assigns to Assignee, and Assignee hereby accepts, all of Assignor's right, title, and interest in and to the following:

(a) all rights, privileges, and protections of any kind whatsoever of Assignor accruing under the Invention and any intellectual property rights therein, provided under the applicable law of any jurisdiction, bylaw, international treaties, conventions or otherwise throughout the world;

(b) the Applications, all patents that issue from the Applications, and all continuations, continuations-in-part, divisionals, extensions, substitutions, reissues, re-examinations and renewals, of any of the foregoing, and any patents or patent applications from which any of them claim priority or that claim priority from any of them, and all inventions disclosed and claimed in any of the foregoing, and the right to claim priority to any of the foregoing;

(c) all rights, privileges, and protections of any kind whatsoever of Assignor accruing under any of the Applications provided under the applicable law of any jurisdiction, by international treaties and conventions and otherwise throughout the world, including, but not limited to, the right to file foreign patent applications and license recordings; and

(d) any and all claims and causes of action, with respect to the Inventions or the Applications, whether accruing before, on or after the effective date of this Agreement, including all rights to and claims for damages, restitution and injunctive and other legal and equitable relief for past, present and future infringement, misappropriation, violation, misuse, breach or default, with the right but no obligation to petition or sue for, or otherwise seek, such legal and equitable relief and to collect, or otherwise recover, any such damages.

2. Recordation. The Assignor authorizes the Commissioner for Patents and any other governmental officials to record and register this Agreement.

3. Further Actions. The Assignor agrees:

(a) to execute (i) all necessary papers throughout the world to be used in connection with the Applications as Assignee may deem necessary or expedient, (ii) all papers in connection with any interference, legal or other proceedings throughout the world to maintain, protect or enforce, or otherwise relating to, the Applications, and (iii) all papers and documents which may be necessary throughout the world in connection with the preparation and filing of any applications for the Invention and the Applications;

(b) to cooperate with Assignee at Assignee's expense in every way reasonably possible in obtaining evidence related to the Invention and the Applications going forward in any proceedings related to the Applications throughout the world; and

(c) at Assignee's expense to perform all other affirmative acts which in Assignee's reasonable discretion may be necessary or desirable throughout the world to maintain, protect or enforce the Applications or patents granting therefrom.

4. Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

5. Representations and Warranties. The Assignor represents and warrants to the Assignor that: the Assignor has the full right to convey the interest assigned by this Assignment; and that the Assignor has not granted any license to the Invention or the Applications.

6. Successors and Assigns. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns.

7. Choice of Law. This Agreement and any non-contractual obligations arising out of or in connection with it will be governed by and construed in accordance with the laws of England, without taking account of any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The courts of England will have non-exclusive jurisdiction to settle any disputes which may arise out of or in connection with this Agreement. The parties irrevocably agree to submit to that jurisdiction, save that nothing will prevent either party from seeking injunctive relief or enforcing a judgment of the English courts in any appropriate jurisdiction.

IN WITNESS WHEREOF THE PARTIES HERETO HAVE EXECUTED THIS ASSIGNMENT

EXECUTED BY ASSIGNOR



Date: Jul 23, 2024

Name: Fraser Murray

Witnessed by:



Date: Jul 23, 2024

Name: Veronica Porkess

EXECUTED ON BEHALF OF THE ASSIGNEE BY



Date: Jul 23, 2024

Name: Fraser Murray

Title: Shareholder Woodyett Consulting Limited

Witnessed by:



Date: Jul 23, 2024

Name: Veronica Porkess

SCHEDULE

Application No.	Filing Date	Title
PCT/US2023/025936	22 June 2023	MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88
PCT/US2023/025937	22 June 2023	MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88

ASSIGNMENT

THIS ASSIGNMENT is made

BETWEEN

- (1) **PANDEIA THERAPEUTICS LIMITED** (registered number 11463856) whose registered office is at C/O The Cambridge Partnership Limited, The Dorothy Hodgkin Building, Babraham Research Campus, Babraham, Cambridge, UK CB22 3FH ("**Assignor**")
- (2) **ACADIA PHARMACEUTICALS INC.**, whose corporate headquarters are based at 12830 El Camino Real, Suite 400, San Diego, CA 92130 ("**Assignee**")

BACKGROUND

- (A) The parties are entering into this Assignment to confirm the vesting of the Invention(s) and the Applications in the Assignee on the terms set out in this Assignment.

OPERATIVE PROVISIONS

1. In this Assignment, the following expressions have the following meanings unless inconsistent with the context:

Applications means the applications listed in the **Schedule** to this Assignment.

Invention(s) means the invention(s) specified in the Applications.

Patents means granted patents or similar registered rights which derive from any of the Applications and any other application for a patent or similar registered right for the Invention(s) or any applications for continuations, divisionals, reissues, re-examinations, extensions, substitutions and continuations in part in respect of any such application.

2. In consideration of good and valuable consideration of ten pounds sterling, the receipt and sufficiency of which is acknowledged by the Assignor, the Assignor assigns to the Assignee (to the extent that they have not already vested in the Assignee at law or under contract) all its worldwide right, title and interest in the Invention(s) and the Applications absolutely and the full and exclusive benefit of the Invention(s) and the Applications including, without limitation:
 - 2.1 all rights to apply for patents or similar registered rights for the Invention(s) and to prosecute the Applications and such other applications to obtain Patents throughout the world, including the right to priority, and any priorities claimed by such applications so that the grant of any Patent shall be in the name of and vest in the Assignee or its successor(s) in title or assignee(s); and
 - 2.2 all rights to any and all future applications for continuations, divisionals, reissues, re-examinations, extensions, substitutions and continuations in part in respect of the Invention(s) and the Applications (and any part of them) as well as the worldwide right to be granted and hold Patents; and
 - 2.3 all rights and powers arising or accrued from the Invention(s) and the Applications and any

Patents before, on, or after the date of this Assignment, including any right:

2.3.1 to bring, make, oppose, defend, appeal proceedings, claims or actions; and

2.3.2 to obtain relief (damages and other remedies) in respect of infringement or alleged infringement of, or any other cause of action

arising from ownership of, all or any of rights in the Invention(s) and the Applications, including (without limitation) any right to have the benefit of any relief obtained on such infringement before the date of this Assignment.

3. The Assignee accepts the assignment of the Invention(s) and the Applications and all other rights assigned by this Assignment.
4. The Assignor agrees that it will promptly:
 - 4.1 execute all documents, take all such actions and proceedings, do all things and provide all reasonable assistance to secure the right, title and interest in the Invention(s) assigned to the Assignee by this Assignment, including:
 - 4.1.1 registration of the Assignee as applicant for the Applications and any other application for a patent or similar registered rights for the Invention(s), or as proprietor of the Patents; and
 - 4.1.2 assisting the Assignee in obtaining, defending and enforcing the Patents, and assisting with any other proceedings which may be brought by or against the Assignee against or by any third party relating to the rights assigned by this Assignment; and
5. The rights transferred by this Assignment and the benefits of this Assignment will be enforceable by the Assignee together with any successor(s) in title or assignee(s).
6. The failure to exercise or delay in exercising a right or remedy under this Assignment shall not constitute a waiver of the right or remedy or a waiver of any other rights or remedies, and no single or partial exercise of any right or remedy under this Assignment shall prevent any further exercise of the right or remedy or the exercise of any other right or remedy.
7. All headings in this Assignment are for ease of reference only and will not affect the construction or interpretation of this Assignment.
8. This Assignment and any non-contractual obligations arising out of or in connection with it shall be governed by and construed in accordance with the laws of England.
9. The courts of England and Wales will have non-exclusive jurisdiction to settle disputes which may arise out of or in connection with this Assignment. The parties irrevocably agree to submit to that jurisdiction, save that nothing shall prevent either party from seeking injunctive relief in any appropriate jurisdiction.

ON AGREEMENT
Signatures on page 3

IN WITNESS WHEREOF THE PARTIES HERETO HAVE EXECUTED THIS ASSIGNMENT

EXECUTED BY ASSIGNOR



Date: Jul 26, 2024

Name: Jennifer Rhodes

Title: Director, Pandeia Therapeutics Limited

Witnessed by:



Date: Jul 26, 2024

Name: Diane DeWitt

EXECUTED ON BEHALF OF THE ASSIGNEE BY



Date: Jul 26, 2024

Name: Jennifer Rhodes

Title: EVP, Chief Legal Officer, Acadia Pharmaceuticals, Inc.

Witnessed by:



Date: Jul 26, 2024

Name: Diane DeWitt

Schedule

Application No.	Filing Date	Title
PCT/US2023/025936	22 June 2023	MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88
PCT/US2023/025937	22 June 2023	MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88